Skip to main content
Explore URMC


Lymphoma: A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies

Research Question:
Will the new study drug, eFT508, be useful as a cancer treatment in the future?

Basic Study Information

This research study has two parts. Part 1 will test the safety and tolerability of the study drug at different doses and using different ways of taking the drug (powder mixed with a liquid diluent [suspension] taken once per day or capsules taken once or twice per day) to determine the recommended dose. Part 2 will test what effects the study drug has on the cancer and the safety of the study drug when given at the recommended dose.

Location: Cancer Center
Study Web URL:
Study Reference #: ILYM17002

Lead Researcher (Principal Investigator)

Lead Researcher: Paul Barr

Study Contact Information

Study Coordinator: Yelena Lerman
Phone: (585) 276-8333

Additional Study Details

Learn More About These Conditions

More information about Lymphoma

Return to Search